PeproMene Bio, Inc., a clinical-stage biotech company, has announced the successful completion of the first dose cohort in its phase 1 clinical trial for PMB-CT01 (BAFFR-CAR T Cells), a novel therapy designed to treat relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL). This milestone was achieved without any observed Dose Limiting Toxicity (DLT), allowing the trial to proceed to the next phase.

The trial, known as PMB-102, is being conducted at City of Hope, a leading cancer research and treatment institution. PeproMene licensed the intellectual property for PMB-CT01 from City of Hope. In the first cohort, 50x106 PMB-CT01 was administered, and the therapy was well-tolerated with minimal toxicity. Notably, all three patients in this cohort showed positive responses to treatment, with a 100% Overall Response Rate at one month post-treatment, including two Complete Responses and one Partial Response.

PMB-CT01 represents a potential breakthrough in treating B-cell malignancies. Unlike previous therapies, it targets BAFF-R (B Cell Activating Factor Receptor), a receptor found primarily on B cells, making it difficult for tumor cells to evade immune responses through the loss of this receptor. This unique approach offers hope for patients who have relapsed after CD19 CAR T-cell therapy, addressing an unmet medical need.

The promising results in this early stage of the trial align with preclinical research data from City of Hope, demonstrating PMB-CT01's ability to overcome CD19 antigen loss in B-cell malignancies. PeproMene's commitment to advancing this therapy underscores its potential as a new option for patients with B-cell lymphoma.

PeproMene Bio, Inc. is based in Irvine, California, and is focused on developing innovative therapies for cancers and immune disorders. PMB-CT01 is currently being investigated in phase 1 clinical trials for B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin's lymphoma (B-NHL). Additionally, PeproMene is working on other promising therapies, including BAFFR Bispecific T Cell Engager and BAFFR-CAR NK cells.